HDLコレステロールキットの世界市場：2024年～2031年

市場概要

HDLコレステロールキットの世界市場は、2023年に6億4,702万米ドルに達し、2031年には10億568万米ドルに達すると予測され、予測期間2024年～2031年のCAGRは5.8%で成長すると予測されています。

血漿リポ蛋白質には多くの主要なタイプがあり、そのひとつが高密度リポ蛋白質（HDL）です。HDLは、大きさ、脂質およびアポリポ蛋白質の含有量が異なり、コレステロールを含む多くの異種粒子で構成されています。HDLはコレステロールを末梢細胞から肝臓に運び、そこで胆汁酸に変化して腸から排出する役割を担っています。

HDL-Cの正確な評価は、患者の冠動脈性心疾患のリスクを判定するために不可欠です。沈殿法の代わりに直接測定を用いれば、精度と再現性が向上します。通常、HDLはコレステロールやトリグリセリドやLDLを含む脂質プロファイルなどの追加検査と一緒にオーダーされます。HDLと総コレステロールを一緒に測定することは、心臓病リスクのスクリーニングツールとして非常に有用です。

市場力学：

促進要因

心血管疾患の有病率の上昇

世界人口の増加、特に高齢者人口の増加に伴い、脳卒中、アテローム性動脈硬化症、冠動脈疾患、心臓発作などの心血管疾患の発生率も上昇し、医療介入に対する大きな需要が生じると予想されます。国連の統計によると、2030年までに世界人口は85億人に達し、2050年には97億人になると予測されています。世界保健機関（WHO）の推計によれば、60歳以上の老齢人口は2030年には14億人近くになり、2050年には21億人になります。

心血管系疾患の大部分は、低比重リポ蛋白（LDL）、超低比重リポ蛋白（VLDL）、トリグリセリド、コレステロールが主な原因となっています。これらが蓄積すると、体の各部位への血液循環が滞り、深刻な病的状態に陥る。善玉コレステロールとしても知られる高比重リポ蛋白（HDL）は、悪玉コレステロール、特にLDLの濃度を下げることが知られています。このHDLは、血管内で血栓を形成するLDLを分解して肝臓に運び、LDLは隔離されて体外に排出されるか、脂質細胞の形で貯蔵されます。

HDL-Cの検査は、心臓病のリスクなど、患者の心血管系の健康状態を評価するために行われます。善玉コレステロール、すなわちHDL-Cは冠動脈性心疾患の発症リスク低下と関連しています。HDL-Cと非HDLコレステロールの比率は、同じ血液サンプルで総コレステロールとHDL-Cの両方を測定することにより、医師が容易に計算することができ、患者の心血管系の健康を評価するために不可欠です。

人口の高齢化、座りがちなライフスタイル、現代社会における食習慣の変化は、心血管疾患の発症リスクを高めると予想されています。

例えば、米国心臓協会（American Heart Association, Inc.）によると、世界全体で約1,800万人の死亡が心血管疾患（CVD）に起因しており、高所得国（HIC）と低所得国（LMIC）では大きな差があります。LMICsは心血管疾患（CVDs）の世界の負担のうち不釣り合いな部分を担っており、世界の心血管疾患による死亡の80％を占めています。

また、オーストラリア国立心臓財団によれば、オーストラリア人の6人に1人が心血管疾患を抱えており、その数は約450万人で、オーストラリア全人口の18％に相当します。さらに、オーストラリアでは1,500人以上の入院患者と全死亡者の24％がCVDに起因しています。

この動向は今後も続くと予想され、心臓の健康状態をタイムリーにモニタリングするなどの予防的な健康対策への需要が高まることが予想され、予測期間中にHDLコレステロール検査キットへの大きな需要が創出されることが期待されます。

抑制要因

HDLコレステロール検査キットの高価格は、市場成長を阻害する可能性のある抑制要因の1つです。これは、運営予算の少ない小規模な医療センターや診療所にとっては経済的負担となり得る。加えて、定期的なコレステロール検査の重要性に関する患者、特に地方に住む患者の認識不足も市場成長を抑制する要因の1つです。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 心血管疾患の有病率の上昇
    • 技術的進歩の高まり
  • 抑制要因
    • ヘルスケアに対する認識不足とアクセス制限
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• アンメットニーズ
• PESTEL分析
• 特許分析
• SWOT分析

第6章 COVID-19分析

第7章 タイプ別

• 比色法
• 蛍光法
• 沈殿法
• その他

第8章 サンプルタイプ別

• 血清
• 血漿
• 尿
• その他

第9章 エンドユーザー別

• 病院
• 専門クリニック
• 診断センター
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• F. Hoffmann-La Roche Ltd
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Thermo Fisher Scientific Inc.
• Abbott
• Merck KGaA
• Randox Laboratories Ltd.
• SEKISUI Diagnostics
• Abcam Limited.
• Diazyme Laboratories, Inc.
• Cell Biolabs, Inc.
• DiaSys Diagnostic Systems GmbH

第13章 付録

Market Overview

The Global HDL Cholesterol Kits Market reached US$ 647.02 million in 2023 and is expected to reach US$ 1,005.68 million by 2031, growing at a CAGR of 5.8% during the forecast period 2024-2031.

Plasma lipoproteins include many primary types, one of which is high-density lipoproteins (HDL). They vary in size and lipid and apolipoprotein content and are made up of many heterogeneous particles, including cholesterol. HDL is responsible for transferring cholesterol from peripheral cells to the liver, where it is transformed into bile acids and eliminated through the intestines.

Precise evaluation of HDL-C is essential for determining a patient's risk of coronary heart disease. When direct measurement is used instead of precipitation techniques, accuracy and repeatability are increased. Typically, HDL is ordered in conjunction with additional tests, such as those for cholesterol or lipid profiles that include triglycerides and LDL. HDL and total cholesterol together are a highly helpful screening tool for heart disease risk.

Market Dynamics: Drivers

Rising prevalence of cardiovascular conditions

As the global population is rising especially the old-age demographic, the incidence of cardiovascular conditions such as stroke, atherosclerosis, coronary artery disease, and heart attack are also expected to rise, creating a huge demand for medical intervention. As per the United Nations statistics, by 2030, the global population is predicted to reach 8.5 billion and in 2050 to 9.7 billion. As per the World Health Organization (WHO) estimates, the old-age population above 60 years would be nearly 1.4 billion in 2030 and 2.1 billion in 2050.

The major culprit behind majority of the cardiovascular conditions is low-density lipoprotein (LDL), very low-density lipoproteins (VLDL), triglycerides, and cholesterol. Accumulation of these will lead to blockage of blood circulation to various parts of the body that results in serious morbid conditions. The high-density lipoprotein (HDL), also known as good cholesterol, is known to reduce the levels of bad cholesterol, especially LDL. This HDL helps to break down the LDL that forms thrombus in the blood vessels and transport it back to the liver, where the LDL is sequestered and eliminated from the body or stored in the form of lipid cells.

Testing for HDL-C is done to evaluate the patient's cardiovascular health, including their risk of heart disease. Good cholesterol, or HDL-C, is linked to a decreased risk of coronary heart disease events. The ratio of HDL-C to non-HDL cholesterol may be readily computed by the physician by measuring both total cholesterol and HDL-C in the same blood sample, which is vital for evaluating the patient's cardiovascular health.

The aging population demographic, sedentary lifestyle, and change in eating habits in the modern world are expected to increase the risk of cardiovascular disease incidence.

For instance, American Heart Association, Inc. states that around 18 million deaths globally are attributed to cardiovascular disease (CVD), with significant differences between high- and low-income countries (HICs) and LMICs. LMICs bear a disproportionate amount of the global burden of cardiovascular diseases (CVDs), accounting for 80% of all cardiovascular deaths globally.

In addition, as per the National Heart Foundation of Australia, one in six Australians is living with a cardiovascular disease accounting for nearly 4.5 million cases, which represent 18% of the total Australian population. In addition, more than 1500 hospital admissions and 24% of all deaths in Australia are attributed to CVD.

As this trend is expected to rise, the demand for preventative health measures is expected to rise that include timely heart health monitoring, is expected to create a huge demand for HDL cholesterol testing kits in the forecast period.

Restraints

The high cost of HDL cholesterol kits is one of the restraining factors that may hinder market growth. This can be an economic burden to small-scale health centers and clinics with low operational budgets. In addition, the lack of awareness among patients especially those living in rural areas regarding the importance of regular cholesterol checkups is another factor that may restrain the market growth.

Segment Analysis

The global HDL cholesterol kits market is segmented based on product type, modality, end-users, and region.

The colorimetry based kits in the type segment accounted for approximately 56.4% of the global HDL cholesterol kits market share

HDL cholesterol is routinely evaluated together with total cholesterol, LDL cholesterol, and triglycerides to track each patient's unique risk of developing cardiovascular disease. The most popular method for measuring HDL cholesterol is enzymatic colorimetric techniques, the gold standard for lipid analysis of this kind. Since the development of color is the endpoint in this process, the intensity, and other parameters can be estimated by employing ultraviolet-visible spectroscopy at 500 nm. This is a widely accepted method due to its simplicity, cost-effectiveness, sensitivity, and specificity. Moreover, many HDL detection kits manufactured by prominent players utilize the colorimetric method.

Geographical Analysis

North America is expected to dominate the market with a 43.2% share in the global HDL cholesterol kits market

North America is expected to dominate the market due to its well-advanced healthcare infrastructure, state-of-the-art diagnostic centers, clinical laboratories, etc. Moreover, the the major high-income countries in the region the U.S. and Canada are well-known for their investments in the healthcare industry

For instance, Laboratory Corporation of America Holdings has nearly 2,000 centers spanning across the U.S. providing several diagnostic testing services including the cholesterol panel. Quest Diagnostics, another prominent diagnostic service provider has over 2,000 of its patient service centers and nearly 7,400 patient access points in the U.S.

This well-established network of clinical laboratories provides testing services all across the nation making the service easily accessible by all the population.

Moreover, the region is known for its high prevalence of cardiovascular-related events. As per the American Heart Association's heart disease and stroke statistics 2024 update, nearly 222.4 per 100,000 patients age-adjusted death rate attributable to CVD, and nearly 25.5% of the U.S. adult population have their LDL-cholesterol greater than 130mg/dL. Low-density lipoprotein (LDL) is the major culprit in the majority of cardiovascular conditions such as ischemia, atherosclerosis, and stroke. Moreover, nearly 9.7 million people in the U.S. have undiagnosed diabetes, 29.3 million people have been diagnosed with diabetes and 115.9 million people are at risk of pre-diabetes.

Considering the high prevalence of cardiovascular indications, and the well-established healthcare systems combined with top-tier clinical laboratories providing HDL testing services the demand and the sales volume of HDL cholesterol kits is far higher in the North American region. In addition, most market leaders have established a stronghold market position in the region, making the kits easily available to healthcare facilities. All these factors are expected to be contributing to the region's dominance in the global market for HDL cholesterol kits.

Covid-19 Analysis

The Covid-19 pandemic had a significant impact on the market of HDL cholesterol kits. During the pandemic, the global supply chain has been disrupted due to imposed restrictions on movement and lockdowns. The restriction in movement has reduced the hospital and clinical laboratory visits by the patients, which is anticipated to have resulted in decreased HDL cholesterol testing volumes. Moreover, the clinical labs and hospitals were majorly focused on providing testing services to the Covid-infected patients which is anticipated to have resulted in decreased testing volume.

For instance, a study conducted in the Mass General Brigham (MGB) which is a large integrated healthcare system serving Massachusetts and its neighboring states, has found a 39.2% decline in weekly cholesterol tests from 6,361 in 2019 to 3,867 in 2020, with the greatest reductions occurring during the first wave of the pandemic accounting for 92% reduction in the testing volume.

Market Segmentation

By Type

• Colorimetry Based Kits
• Fluorometry Based Kits
• Precipitation Based Kits
• Others

By Sample Type

• Serum
• Plasma
• Urine
• Others

By End-Users

• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major players in the HDL cholesterol kits market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott, Merck KGaA, Randox Laboratories Ltd., SEKISUI Diagnostics, Abcam Limited., Diazyme Laboratories, Inc., Cell Biolabs, Inc. and DiaSys Diagnostic Systems GmbH among others.

Why Purchase the Report?

• To visualize the global HDL cholesterol kits market segmentation based on type, sample type, end-users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of HDL cholesterol kits market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global HDL cholesterol kits market report would provide approximately 62 tables, 55 figures, and 187 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Sample Type
• 3.3. Snippet by End-Users

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising prevalence of cardiovascular conditions
    • 4.1.1.2. Rising technological advancements
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of awareness and limited access to healthcare
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs
• 5.6. PESTEL Analysis
• 5.7. Patent Analysis
• 5.8. SWOT Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Colorimetry Based Kits*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Fluorometry Based Kits
• 7.4. Precipitation Based Kits
• 7.5. Others

8. By Sample Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
  • 8.1.2. Market Attractiveness Index, By Sample Type
• 8.2. Serum*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Plasma
• 8.4. Urine
• 8.5. Others

9. By End-Users

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
  • 9.1.2. Market Attractiveness Index, By End-Users
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Specialty Clinics
• 9.4. Diagnostic Centers
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.5.1. Germany
    • 10.3.5.2. UK
    • 10.3.5.3. France
    • 10.3.5.4. Italy
    • 10.3.5.5. Spain
    • 10.3.5.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.5.1. Brazil
    • 10.4.5.2. Argentina
    • 10.4.5.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.5.1. China
    • 10.5.5.2. India
    • 10.5.5.3. Japan
    • 10.5.5.4. South Korea
    • 10.5.5.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. F. Hoffmann-La Roche Ltd
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Thermo Fisher Scientific Inc.
• 12.3. Abbott
• 12.4. Merck KGaA
• 12.5. Randox Laboratories Ltd.
• 12.6. SEKISUI Diagnostics
• 12.7. Abcam Limited.
• 12.8. Diazyme Laboratories, Inc.
• 12.9. Cell Biolabs, Inc.
• 12.10. DiaSys Diagnostic Systems GmbH (LIST NOT EXHAUSTIVE)

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us